HUDSON, Mass. and YOKNEAM ILLIT, Israel — March 13, 2026 — Leads & Copy — Lifeward Ltd. (Nasdaq: LFWD) announced that its shareholders have approved the issuance of ordinary shares to finalize its strategic partnership agreement with Oramed Pharmaceuticals Inc. (Nasdaq: ORMP).
The partnership, which is moving toward closing, is expected to position Lifeward as a diversified biomedical innovation company with a clear path to profitability. It also integrates Oramed’s Protein Oral Delivery (POD™) technology to expand Lifeward into biotech markets, with Oramed funding the platform’s clinical development. Lifeward is expected to gain access to up to $47 million of capital through the agreement.
According to Mark Grant, President and CEO of Lifeward, this partnership is a defining moment for the company. Grant believes Lifeward is now positioned to combine its medical technology platform with the potential of the POD™ oral delivery technology.
Grant stated the company is focused on driving profitability across its neuro-rehabilitation business while investing in technologies that can reshape therapeutic markets. He believes this transaction provides the foundation and framework to pursue that vision.
Under the agreement, Lifeward will integrate Oramed’s POD™ technology, and Oramed will acquire a significant equity ownership in Lifeward through shares and prefunded warrants. The investment structure could provide Lifeward with access to approximately $47 million from Oramed and another investor through equity, convertible notes, milestone-based funding, and warrant coverage.
The partnership is intended to provide Lifeward with additional financial resources and flexibility to execute its path to profitability. This will be driven by its medical technology product portfolio, including the ReWalk® exoskeleton and AlterG® anti-gravity systems, and its powered upper body exoskeleton.
The POD™ platform’s integration will expose Lifeward to a biotechnology opportunity focused on enabling oral delivery of biologic drugs that currently require injection.
The POD™ technology is designed to allow therapeutic proteins, such as insulin, to be delivered orally by enabling them to pass through the gastrointestinal tract and into the bloodstream, potentially transforming treatment approaches for multiple chronic diseases.
The POD™ platform has been evaluated in clinical development programs focused on diabetes, including ORMD-0801, a potential oral insulin therapy. The global diabetes market exceeds $80 billion annually, with injectable insulin representing a substantial portion.
Under a clinical trial management agreement to be entered into at closing, Oramed will retain responsibility for managing and funding the POD™ platform’s clinical development program. This structure will allow Lifeward to maintain operational focus on growing its existing MedTech business while retaining exposure to the potential upside of the biotechnology platform.
With the transaction’s closing, Lifeward will become a biomedical portfolio company focused on: driving sustainable profitability from its existing MedTech product portfolio; deploying capital selectively toward innovative assets with defined development milestones; and building a diversified biomedical portfolio that balances near-term revenue generation with biotechnology innovation opportunities.
Lifeward anticipates closing the transaction following the satisfaction of additional customary closing conditions.
Lifeward designs, develops, and commercializes life-changing solutions that span the continuum of care in physical rehabilitation and recovery. Founded in 2001, Lifeward has operations in the United States, Israel, and Germany.
Lifeward®, ReWalk®, ReStore® and Alter G® are registered trademarks of Lifeward Ltd. and/or its affiliates.
Source: Lifeward
